News provided by Clover Biopharmaceuticals Mar 24, 2021, 02:15 ET Over 22,000 participants aged 18 years or older are expected to be enrolled in SPECTRA across Latin America, Asia, Europe and Africa Interim analysis of the primary endpoint expected in the middle of 2021 CHENGDU, China and EMERYVILLE, Calif., March… Read More
Series C financing brings total capital raised in the last 12 months to over US$ 400 million (>RMB 2.5 billion) The proceeds will support the continued development and expansion of Clover’s pipeline of protein-based vaccines and biologic cancer therapies CHENGDU, CHINA, February 23, 2021—Clover Biopharmaceuticals, a global clinical-stage biotechnology company… Read More
2021-02-05 22:57 The Board of Directors (the “Directors”) of China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that on 1st February 2021, the Group through a wholly-owned subsidiary of the Company acquired all the issued and outstanding shares of Luqa Ventures Co., Limited… Read More
Study results expected to be presented in mid-2021 ATLANTA, Jan. 25, 2021 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today announced that it has completed the Phase 1b clinical trial of ATI-2173, an Active Site Polymerase Inhibitor Nucleotide (ASPIN), in patients with chronic hepatitis B virus (HBV) infection. The Company… Read More
December 21, 2020 02:00 ET | Source: Allecra Therapeutics GmbH; Shanghai Haini Pharmaceutical Co., Ltd. Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with… Read More
Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential backbone of a curative regimen for Hepatitis B (“HBV”) ATLANTA, Dec. 01, 2020 (GLOBE NEWSWIRE) — Antios Therapeutics, Inc. (“Antios”) today… Read More
PHOENIX, November 6, 2020 – OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, today announced the appointment of Charles (Chuck) M. Baum, M.D., Ph.D., as chairperson of the company’s board of directors. Dr. Baum is currently president and chief executive officer of Mirati Therapeutics, which develops novel therapeutics that target the genetic… Read More
Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge Strong immune response and protection observed with adjuvant systems from GSK and Dynavax led to inclusion of both adjuvants separately into Clover’s ongoing Phase 1 clinical… Read More
BEDFORD, Mass., Sept. 14, 2020 /PRNewswire/ — Rejoni announced today that it has closed a $15 million Series A financing. The round was led by Ascension Ventures, with additional participation from Delos Capital and Sparta Group. Rejoni is using its biomaterials expertise to realize medical devices that improve the outcomes of minimally… Read More
CEPI to invest an additional $66m upfront in Clover’s S-Trimer protein vaccine candidate. Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year. July 08, 2020 04:00 AM Eastern Daylight Time OSLO, Norway–(BUSINESS WIRE)–CEPI, the Coalition… Read More
